Announcements Trials
Browse Landscape

Phase

Phase 1/2 30Phase 1 29Phase 2 25Phase 3 9Phase NA 6Phase 4 4Phase 2/3 3Phase EARLY_PHASE1 2

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 117Neoplasms 101Prostatic Neoplasms 76Carcinoma, Non-Small-Cell Lung 75Colorectal Neoplasms 73Carcinoma, Hepatocellular 67Leukemia, Myeloid, Acute 59Stomach Neoplasms 52Neoplasm Metastasis 50Lung Neoplasms 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Pancreatic Neoplasms 40Recurrence 36Head and Neck Neoplasms 32Rectal Neoplasms 30Colonic Neoplasms 30Leukemia 29Multiple Myeloma 28Ovarian Neoplasms 26Lymphoma 25Squamous Cell Carcinoma of Head and Neck 24Hematologic Neoplasms 23Melanoma 22Urinary Bladder Neoplasms 20Liver Neoplasms 20Polycystic Ovary Syndrome 19Myelodysplastic Syndromes 19Lymphoma, Large B-Cell, Diffuse 19Esophageal Neoplasms 19Uterine Cervical Neoplasms 16

Interventions

dehydroftorafur 1Watchful Waiting 1Taxes 1Radiotherapy, Intensity-Modulated 1Platinum 1Paclitaxel 1Gemcitabine 1Fluorouracil 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Epstein-Barr Virus Infections × Clear all
NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05305040 2024-05-16

Prevent

AlloVir

Phase 2/3 Terminated
451 enrolled 10 charts

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT04693637 2024-05-09

Prevent

AlloVir

Phase 2/3 Completed
26 enrolled 16 charts

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡